SINGAPORE, June 24, 2024 /PRNewswire/ -- Singapore-headquartered Juniper Biologics Pte
Ltd (Juniper), a leading healthcare and pharmaceuticals company
focused on commercialising novel therapies, has been granted
distribution rights for Caris Life Sciences (Caris)' solid tumour
molecular profiling services in the Middle East and Africa (MEA). Caris is the leading
next-generation AI TechBio company and precision medicine pioneer.
This expansion follows the initial January
2023 distribution rights partnership with Caris for the same
services in Southeast Asia (SEA).
Juniper is now poised to offer Caris' advanced solid tumour
molecular profiling services across a broader region, enhancing
patient access to personalised treatment options.
Caris' best-in-class molecular profiling, combined with
proprietary artificial intelligence, provides more precise and
individualized cancer treatments. This profiling approach assesses
DNA, RNA, and proteins, revealing a molecular blueprint that
identifies treatment options specific to each patient's cancer.
Caris has developed the world's largest and most informative
platform for cancer analysis, featuring the most advanced tumour
profiling available, including Whole Exome and Whole Transcriptome
Sequencing across over 23,000 genes. By analysing biomarkers found
in tumours, Caris helps healthcare providers make informed choices
for personalised care.
Juniper Biologics is committed to driving positive change in the
pharmaceutical industry on a global scale. Aligned with its mission
to deliver transformative therapies through bold scientific
innovation, Juniper's collaboration with Caris will enhance access
to quality treatments for patient communities in the Middle East and Africa. Juniper continues to pursue impactful
partnerships aimed at uplifting communities and individuals,
especially in underserved regions where access to advanced
therapies is limited.
Raman Singh, Founder and Chief
Executive Officer (CEO) of Juniper Biologics, spoke on the
successful acquisition: "Caris molecular profiling bridges the gap
between tumour biology and cancer treatments, guiding precision
medicine through personalised treatment selection for physicians
and their patients. Our exclusive partnership with Caris Life
Sciences to distribute this service in the Middle East and Africa will significantly empower healthcare
professionals to make informed decisions for their patients. This
service enables oncologists to recommend highly personalised
treatments that specifically target a patient's cancer, thereby
improving and expanding their care options. This targeted approach
offers patients, particularly those with rare or aggressive
cancers, an improved quality of life."
"Caris is pleased to expand the distribution of our molecular
profiling services in the Middle
East and Africa through our
partnership with Juniper Biologics," said Caris President
David Spetzler, MS, PhD, MBA. "This
collaboration aligns with Caris' goal of enabling clinicians
worldwide to make the best individualised treatment choices for
their patients and ultimately helping to improve patient
outcomes."
This partnership marks a significant milestone in expanding
access to personalised medicine and advanced cancer treatment
technologies in the Middle East
and Africa.
About Juniper Biologics
Backed by The Sylvan Group, Juniper Biologics is a science-led
healthcare company focused on delivering novel therapies to improve
the health and quality of life of patients, by building a growing
presence in Oncology and Oncology Supportive Care, Rare/Orphan
Diseases and Gene Therapy. It was founded on a vision to provide
treatments for unmet medical needs focused on specialist therapy
areas in which it can make the most difference. Through bold and
transformative science, Juniper Biologics is committed to creating
possibilities that have the potential to become the next generation
of life-changing medicines for patient communities in China, Japan,
Asia, Australia, New
Zealand, Middle East, and
Africa.
Website: https://www.juniperbiologics.com/
LinkedIn: https://www.linkedin.com/company/juniper-biologics
About Caris Life Sciences
Caris Life Sciences® (Caris) is the leading
next-generation AI TechBio company and precision medicine pioneer
actively developing and delivering innovative solutions to
revolutionize healthcare and improve the human condition using
molecular science and AI. Through comprehensive molecular profiling
(Whole Exome and Whole Transcriptome Sequencing) and the
application of advanced AI and machine learning algorithms, Caris
has created the large-scale, multi-modal database and computing
capability needed to analyse and unravel the molecular complexity
of disease. This convergence of sequencing power, big data, and AI
technologies provides an unmatched platform to deliver the next
generation of precision medicine tools for early detection,
diagnosis, monitoring, therapy selection, and drug development.
Headquartered in Irving, Texas,
Caris has offices in Phoenix, New
York, Cambridge (MA),
Tokyo, Japan and Basel, Switzerland. Caris or its distributor
partners provide services in the U.S., Europe, Asia,
and other international markets. To learn more, please visit
CarisLifeSciences.com.
View original
content:https://www.prnewswire.co.uk/news-releases/juniper-biologics-expands-distribution-rights-for-caris-life-sciences-molecular-profiling-in-the-middle-east-and-africa-302179771.html